Connect with us

Technology

BioRadar Names David Relman and Kevin Esvelt Co-Chairs of Scientific Advisory Board

Published

on

Dr. David Relman of Stanford and Dr. Kevin Esvelt of MIT — two of the most respected voices in U.S. biosecurity — will co-chair BioRadar’s Scientific Advisory Board and help lead the science behind its “biological weather service” early-warning platform

BOSTON, Oct. 7, 2026 /PRNewswire-PRWeb/ — BioRadar PBC, a biological intelligence company building an early-warning platform designed to detect biological threats that conventional surveillance miss, today announced that Dr. David Relman of Stanford University and Dr. Kevin Esvelt of MIT will serve as Co-Chairs of the company’s Scientific Advisory Board. As Co-Chairs, they will guide BioRadar’s scientific direction, advise the founding team, and help recruit additional members of the Scientific Advisory Board as the company builds its biological early-warning platform.

“BioRadar succeeds only if the intelligence we provide is rigorous enough that public-health and national-security leaders can trust it and act on it. That is fundamentally a science problem, and there are no two people better suited to help us solve it than David and Kevin.”

“Having the two best scientists on this topic, David and Kevin, will help us build an extraordinary tool that will make biointelligence a reality for our nation and the world,” said Dr. Ashish Jha, Former White House COVID-19 Response Coordinator and Co-Founder of BioRadar.

Leading Voices in Biosecurity

Relman and Esvelt are leading figures in biosecurity, infectious disease and biological risk whose work has helped shape both the science and policy surrounding biological threats.

Relman is the Thomas C. and Joan M. Merigan Professor in Medicine and Professor of Microbiology & Immunology at Stanford University and Chief of Infectious Diseases at the VA Palo Alto Health Care System. He was a founding member of the National Science Advisory Board for Biosecurity and most recently served as Senior Advisor in the White House Office of Pandemic Preparedness and Response Policy.

Esvelt is an Associate Professor at the MIT Media Lab and director of the Sculpting Evolution group. He pioneered the development of CRISPR-based gene drives and has become a leading researcher on catastrophic biological risk, early-warning systems, and technologies designed to strengthen society’s ability to prevent and respond to biological threats.

Built Around Scientific Rigor

For BioRadar, scientific rigor means more than detecting a signal – it means knowing whether that signal can be trusted.

“BioRadar will ultimately succeed only if the biological intelligence we produce is rigorous enough that public-health and national-security leaders can trust it and act on it,” said Jha. “Doing it well is ultimately a science problem — and there’s no one better suited to solving it than David and Kevin.”

“A signal by itself isn’t intelligence,” said Dr. Nikki Romanik, former Deputy Director of the White House Office of Pandemic Preparedness and Response Policy (OPPR), and Co-Founder of BioRadar. “Understanding whether it is meaningful, how confident we should be in it, and whether it warrants attention requires extraordinary scientific precision. Drs. Relman and Esvelt will help us bring that capability to the platform.”

“This team understands both sides of this problem: the science required to identify emerging biological threats and the realities facing decision-makers who have to respond to them,” said Relman. “BioRadar is taking seriously the challenge of producing biological intelligence that is scientifically rigorous, timely, and useful. I’m honored to help guide that effort and build the Scientific Advisory Board around it.”

“We are starting to see real progress on the detection side of this problem,” said Esvelt. “The harder part —the part that determines whether we can protect people — is translating that data into something decision-makers can trust and act on. That’s the gap BioRadar is built to close, and it’s why I am excited to help build the science behind it.”

BioRadar is building a biological weather service: a system that integrates environmental, clinical, behavioral and other data to identify emerging biological threats and give decision-makers earlier situational awareness. The platform is currently live in a pilot program, and the company plans to share additional updates as the platform develops.

About BioRadar

Powered by AI, BioRadar is a biological intelligence company building an early-warning platform designed to identify biological activity and threats that targeted surveillance may miss. The platform combines broad biological sensing with clinical, syndromic, behavioral, public-health and other signals to establish location-specific baselines, identify meaningful changes and provide decision-makers with context around what deserves attention. BioRadar was founded by Ashish Jha, former White House Covid-19 Response Coordinator, and Nikki Romanik, former Deputy Director of the White House Office of Pandemic Preparedness and Response Policy. More information is available at www.bioradar.com.

Media contact: pr@bioradarusa.com

Media Contact

J. Wonacott, BioRadar PBC, 1 3102708186, pr@bioradarusa.com, www.bioradar.com 

View original content:https://www.prweb.com/releases/bioradar-names-david-relman-and-kevin-esvelt-co-chairs-of-scientific-advisory-board-302898278.html

SOURCE BioRadar PBC

Continue Reading

Technology

Infinitus Launches FieldForce to Extend the Reach of Pharmaceutical Sales and Reimbursement Teams

Published

on

By

AI agent solution helps field teams become AI first, preparing for HCP meetings, staying connected between visits, and extending provider and reimbursement support without adding additional headcount

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ — Infinitus, healthcare’s agentic communications platform, today announced FieldForce, a new set of secure AI agents designed to extend the capacity of pharmaceutical field teams. Pharma companies can deploy FieldForce to support sales representatives, field reimbursement managers (FRMs), or both, depending on the needs of their organization. For both roles, FieldForce enables teams to become AI-first, using AI agents to extend their capacity across activities before, after, and in between HCP interactions. Importantly, it gives pharmaceutical companies another way to support more providers while giving HCPs access to information and assistance between field visits that can help them better serve their patients.

Pharmaceutical companies are under growing pressure to increase commercial productivity while managing costs. A May 2026 analysis from Deloitte found that sales representatives spend roughly two-thirds of their workday on activities such as research, product and prescribing information, scheduling, and administrative work, leaving less than one-third for customer interactions.

The pressure to do more with existing resources is also playing out across the industry. One recent analysis found that the 17 largest pharmaceutical companies collectively reduced their workforces by more than 22,000 employees in 2025, as companies looked to improve efficiency and prepare for patent expirations and other market pressures. FieldForce is specifically designed to help organizations like these extend field capacity without requiring a corresponding increase in headcount.

Supporting sales and reimbursement teams around HCP interactions

FieldForce gives sales representatives and FRMs agentic support to help manage the work around HCP interactions. The agents connect with field teams’ CRMs to pull together information for preparation before a meeting, capture notes, and update systems afterward. Additional FieldForce agents can be available for inbound calls 24/7 to support providers by answering questions between visits.

For FRMs, AI agents can answer questions about prior authorization status, claims and reimbursement, and help onboard provider offices with approved access materials. Across these interactions, Infinitus Lens provides same-day compliance monitoring and surfaces trends and insights, such as: prescribing trends per provider or provider tier; emerging question themes or support topics; and recommendations for proactive and compliant content or education that can be shared.

Extending provider reach without adding field headcount

FieldForce is also designed to help pharmaceutical companies support providers who may not have regular contact with a sales representative or FRM. A dedicated AI agent can be available between visits, giving providers a direct path to information and support when a field team member is unavailable. For HCPs, that can mean more timely access to information and reimbursement support as they work to help patients access and navigate their treatment. For pharmaceutical companies, it can expand coverage across a larger provider population without requiring a corresponding increase in field hires.

“Our pharma customers need their field teams to cover more providers while managing significant cost and productivity pressures,” said Ankit Jain, CEO and co-founder of Infinitus Systems. “They’re also seeing that the companies embracing AI are finding new ways to scale and operate more efficiently, making an AI-first approach increasingly essential to staying competitive. FieldForce gives sales and reimbursement teams AI support across the work that happens before, after and in between HCP interactions, extending their capacity so they can spend more of their time on the relationships and issues that require their attention.”

Connecting commercial and medical conversations safely

Infinitus FieldForce is built around the distinction between promotional and medical communications within pharmaceutical organizations. The sales agent can support appropriate promotional conversations with HCPs. When a provider asks a clinical or safety question that falls outside the sales representative’s role, the agent can hand the conversation off to a member of the organization’s Medical Information team along with full context. This gives HCPs a direct path to the appropriate resource while helping sales representatives stay within their role.

Built for pharmaceutical organizations

FieldForce brings Infinitus’s trusted, healthcare-native AI to power internal tools for the first time. AI agents are trained on specific data and resources provided by each individual pharma organization along with Infinitus’s proprietary knowledge graph that leverages historical data from millions of payor interactions. This gives pharmaceutical leaders a consistent source of approved information across provider engagement and reimbursement workflows, while providing a way to measure the impact of AI through metrics such as provider coverage, interactions, and cost per interaction.

In July, Infinitus announced its AI-first, human-backed hub solution, designed to streamline patient, provider, and payor communications traditionally managed through legacy call-center infrastructure. FieldForce extends Infinitus’s AI agent capabilities into pharmaceutical commercial and market access teams, giving sales representatives and FRMs around-the-clock support while helping HCPs get timely answers and support to help patients.

About Infinitus

Infinitus is healthcare’s agentic AI communications platform, coordinating conversations and workflows across providers, health plans, specialty pharmacies, pharmaceutical manufacturers, and patients to make sure care reaches those who need it. Infinitus’s system combines industry-leading safety guardrails with the largest dynamic knowledge graph built on millions of real-world interactions. The company has raised over $100M from investors including Google Ventures, Kleiner Perkins, Andreessen Horowitz, and Coatue. Infinitus was recently named to Fast Company’s World’s Most Innovative Companies and is trusted by over 50% of the Fortune 50 healthcare companies. Learn more at www.infinitus.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/infinitus-launches-fieldforce-to-extend-the-reach-of-pharmaceutical-sales-and-reimbursement-teams-302900497.html

SOURCE Infinitus Systems, Inc.

Continue Reading

Technology

JND AutoRedact™ Wins 2026 Relativity Innovation Award

Published

on

By

AutoRedact recognized for delivering redaction accuracy at scale inside Relativity aiR.

SEATTLE, Oct. 7, 2026 /PRNewswire/ — JND Legal Administration, the U.S. leader in legal management and administration services, announced that its AutoRedact™ AI-assisted redaction tool has received the Relativity Innovation Award in the Act category at Relativity Fest 2026, the premier event in the eDiscovery industry. The Act Award honors solutions that enhance Relativity’s redaction, quality control, reporting, case strategy, or production features, delivering meaningful results.

AutoRedact uses both AI and deterministic rules to find and redact sensitive information like personal data or privileged content within images stored in Relativity aiR (formerly RelativityOne). Legal teams describe in plain language what needs to be redacted, iterate and test the results on sample documents in the Detector Lab, and then apply the calibrated instructions at scale across their document populations. AutoRedact also has a dedicated detector for data subject access requests (DSARs) that redacts personal and sensitive information while keeping the requesting individual’s own data visible, a common and time-consuming challenge in privacy compliance. AutoRedact provides confidence levels for redactions to assist legal teams with focusing their human QC efforts and every redaction can be reviewed and adjusted before documents are produced.

“I’m incredibly grateful to our team, whose expertise and relentless testing made AutoRedact possible,” said Ben Sexton, Senior Vice President of Innovation and Strategy at JND. “We’re excited about what AutoRedact can do for our clients.”

“Innovation at JND has always meant building tools that deliver real, measurable results,” said Jennifer Keough, CEO and Co-Founder of JND. “AutoRedact reflects the ingenuity and dedication of our team, and this award is a testament to their work. We congratulate everyone who made it possible.”

Headquartered in Seattle, JND continues to solidify its status as the industry leader in end-to-end eDiscovery solutions. Its eDiscovery service line supports corporations, law firms, and government agencies in deploying the best solutions and technology to meet their goals using Relativity aiR, the market’s leading cloud-based technology solution. JND is one of only two Relativity Platinum Provider Partners.

This award marks JND’s second Relativity Innovation Award in three years. In 2024, Ben Sexton received the Relativity Innovation Award in the Artificial Intelligence category for his leadership in the adoption and development of generative AI tools in eDiscovery. JND’s team also includes three Relativity AI Visionary award recipients.

To schedule a demo of AutoRedact, contact autoredact@jndla.com.

About JND Legal Administration

JND eDiscovery, a RelativityOne software reseller and a division of JND Legal Administration, a Sedgwick company, is the nation’s foremost legal services and settlement administration solutions provider. JND’s fully-featured Relativity aiR instance and professional services team support a broad network of plaintiff and defendant law firms, corporate legal departments and government agency clients in future-proofing their eDiscovery systems. For more information, visit https://www.jndla.com/ediscovery.

Media Contact:
Joe Sexton
info@jndla.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jnd-autoredact-wins-2026-relativity-innovation-award-302900438.html

SOURCE JND Legal Administration

Continue Reading

Technology

L8P8 Launches Tru8 Connect, Free Messaging That Uses Usernames Instead of Phone Numbers

Published

on

By

Messages are end-to-end encrypted, kept only on users’ phones and deleted after eight days

GLENDALE, Calif., Oct. 7, 2026 /PRNewswire/ — L8P8 Inc. today launched Tru8 Connect, a free messaging feature inside the Loop8 app for iOS and Android. People on Tru8 Connect find each other by username, so neither person ever sees the other’s phone number.

Giving someone your number is a bigger step than it used to be. A phone number can lead to your name, your address and the accounts tied to it. Once you hand it out, you can’t take it back. On Tru8 Connect, if a conversation goes badly, you block the person and that’s the end of it. They never had your number in the first place.

Messages are end-to-end encrypted. Loop8’s servers pass them along but can’t read them, and they delete each message once it’s delivered. After that, the message exists only on the two phones in the conversation, and opening it takes Face ID or a fingerprint. Every message deletes itself eight days after it’s sent.

When the app detects a screenshot or screen recording of a chat or a shared photo, it alerts everyone in the conversation and shows who took it.

“People think twice before giving a stranger their phone number, and they should,” said Zarik Megerdichian, founder and CEO of L8P8. “With Tru8 Connect, you don’t have to. And since we delete messages once they’re delivered, there’s no pile of old conversations sitting on our servers for someone to break into later.”

Tru8 Connect is open to users 16 and older. It’s available now in the Loop8 app, which is free on the App Store and Google Play. Loop8 also includes a password manager and an authenticator, both unlocked with biometrics instead of a master password.

About L8P8 Inc.
L8P8 Inc., based in Glendale, Calif., makes privacy and identity software that uses biometrics in place of passwords. Its products include Loop8, a consumer app, and Loop8ID, an age verification and identity platform for businesses. Learn more at loop8.ai and loop8id.com.

Media Contact
Zarik Megerdichian
L8P8 Inc.
pr@l8p8.com
‪(818) 208-0238‬

View original content to download multimedia:https://www.prnewswire.com/news-releases/l8p8-launches-tru8-connect-free-messaging-that-uses-usernames-instead-of-phone-numbers-302897892.html

SOURCE L8P8 Inc.

Continue Reading

Trending